Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

¤·¹æ¾Ï¿¡¼­ ¿¹ÈÄÀÎÀڷμ­ CD44 ¹× Matrix Metalloproteinase 3(Stromelysin 3)ÀÇ Ç¥Çö¿¡ °üÇÑ ¿¬±¸ Prognostic Signicance of the CD44 and Matrix Metallproteinase 3(Stromelysin 3) Expression in Breast Cancer

´ëÇѾÏÇÐȸÁö 1995³â 27±Ç 4È£ p.593 ~ 601
¹ÚÇý¸², ¼ÕÁøÈñ, ¹Ú¿µÀÇ,
¼Ò¼Ó »ó¼¼Á¤º¸
¹ÚÇý¸² (  ) 
¿ï»ê´ëÇб³

¼ÕÁøÈñ (  ) 
¿ï»ê´ëÇб³
¹Ú¿µÀÇ (  ) 
¿ï»ê´ëÇб³

Abstract


Expression of the CD44 and matrix metalloproteinase 3 were examined in 43 cases of breast carcinoma, Immunohistochemical staining with CD44 antibodies demonstrated diffuse cytoplasmic positivity in tumor cells of intraductal and invasive
carcinoma.
Matrix metalloproteinase 3 was present in invasive cancer cells and surronding stromal cells. Expression of the CD44 and matrix metalloproteinase 3 were moderately correlated. Expression of the CD44 was associated with the large size of primary
tumor(¡Ã2cm), the histologic grade by Bloom-Richardson, the presence of metastatic node, and the clinical stage. Overall five-year survival rate in 43 patients was 74.0¡¾9.6% and the disease free survival curve showed significant difference
according to
the expression of CD44. However, the expression of matrix metalloproteinase 3 was not associated with variable prognostic factors and disease free survival.
From this study, it is concluded that expression of the CD44 and matrix metalloproteinase 3 were associated with invasion of breast cancer and expression of the CD44 could be used as a prognostic indicator in breast cancers. However, the
expression
of
matrix metal-loproteinase 3 had the limited value.

Å°¿öµå

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

 

µîÀçÀú³Î Á¤º¸

KoreaMed
KAMS